# SamaCare

> SamaCare is a San Francisco-based healthcare technology company that runs the leading medical-benefit prior authorization platform for specialty medications. Its cloud-based, AI-assisted software replaces the fax-and-phone paperwork that delays patients from receiving life-changing biologics, automating submission, tracking, benefit verification, and enrollment across major US payers. The platform serves specialty practices in retina, oncology, neurology, and rheumatology, plus pharmaceutical manufacturers who use SamaCare's real-time data to improve patient access.

- **Founded:** 2018
- **Headquarters:** San Francisco, California, United States
- **Founders:** Syam Palakurthy (Co-Founder & CEO)
- **Team size:** ~50 employees
- **Products:** Unified Prior Authorization Platform, Human-in-the-Loop AI, Benefit Verification & Enrollment, Insights & Benchmarks, EMR Integrations
- **Notable:** Handled 2,000,000+ medical-benefit prior authorizations, Reached 31,000+ providers on the platform, Processes $6B+ in annual medical-benefit drug spend

## Products & services

- **Unified Prior Authorization Platform** — Automated submission and real-time tracking of medical-benefit prior authorizations across major US payers, replacing manual paper and fax workflows.
- **Human-in-the-Loop AI** — AI-assisted policy guidance and post-submission follow-up, with people reviewing edge cases to improve approval accuracy.
- **Benefit Verification & Enrollment** — Workflow automation for verifying patient benefits and managing enrollment for specialty drugs.
- **Insights & Benchmarks** — Real-time data analytics on prior-authorization outcomes used by pharmaceutical manufacturers for market access.
- **EMR Integrations** — Connections with electronic medical records and healthcare platforms so practices work inside existing systems.

## Achievements

- Handled 2,000,000+ medical-benefit prior authorizations
- Reached 31,000+ providers on the platform
- Processes $6B+ in annual medical-benefit drug spend
- 84% faster time to resolution for prior authorizations
- 29% higher approval rate; 24% lower patient churn/abandonment
- Raised $34.8M total across funding rounds
- Partners with roughly 40% of leading pharmaceutical companies

## Latest updates

- **2024-05** — Closed $17M Series B led by Questa Capital to scale the specialty-drug prior authorization platform.
- **2022-06** — Closed $12M Series A led by Vive Collective; Cheryl Cheng joined the board.

## Links

- Website: https://www.samacare.com/
- LinkedIn: https://www.linkedin.com/company/sama-health/

---

Profile page: https://yespress.io/samacare
Published by YesPress — https://yespress.io
Last updated: 2026-06-12